Piv­otal fail­ure trig­gers job cuts at San Diego-based Toca­gen

Toca­gen is cir­cling the drain, fol­low­ing the crush­ing late-stage fail­ure of its ex­per­i­men­tal brain can­cer ther­a­py last month. On Thurs­day, the San Diego-based com­pa­ny slashed its work­force by 65%.

Its two-part ther­a­py was be­ing test­ed in pa­tients with re­cur­rent high-grade glioma un­der­go­ing re­sec­tion in the To­ca 5 study. On av­er­age, pa­tients on the Toca­gen reg­i­men ac­tu­al­ly did not live as long as those giv­en stan­dard treat­ment (11.1 months me­di­an com­pared to 12.2 months). In ad­di­tion, the com­pa­ny’s ther­a­py hit a haz­ard ra­tio of 1.06, re­flect­ing an in­creased risk to pa­tients, along with an un­sa­vory p-val­ue of 0.6154.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.